Generics

The report from the Association for Accessible Medicines highlights the impact that accessible generic and biosimilar medicines have had on patients nationwide.

Labetalol HCl injection, 100 mg/20 ml and 200 mg/40 ml vial had a market value of approximately $6 million in the 12 months ended March 2021, according to IQVIA.

The launch marks the world’s first biosimilar antibody drug conjugate of trastuzumab emtansine.

The moxifloxacin ophthalmic solution had a market value of approximately $34 million for the 12 months ended March 2021, according to IQVIA.

Natco received the Food and Drug Administration's green light for generic Revlimid and Zortress.

Camber's generic Strattera provides a treatment for attention-deficit hyperactivity disorder.

Erik Komendant will assume the role of the Association for Accessible Medicines’ senior vice president of government affairs and Steven Selde will serve as director of the Biosimilars Council.

Firazyr injection had a market value of roughly $223.4 million for the 12 months ended March 2021, according to IQVIA.